Mereo BioPharma Group plc reported a net loss of $0.01 per share for the quarter ended December 31 2025, a figure that matches the consensus estimate and confirms the company’s ongoing pre‑revenue status. The company generated no product revenue during the period, and its cash and cash equivalents stood at $41.0 million, giving the firm a runway that now extends into mid‑2027 rather than the 12‑13 months previously cited.
The full‑year 2025 loss of $41.9 million is slightly lower than the $43.3 million loss reported for 2024, indicating a modest improvement in operating performance. Cash balances remained flat at $41.0 million, and the extended runway reflects the company’s ability to fund its development pipeline for an additional 18–20 months at current burn rates.
R&D spending remained high, driven primarily by the setrusumab program. The Phase 3 Orbit and Cosmic trials missed their primary fracture endpoints, but the data show significant gains in bone mineral density, reductions in vertebral fractures, and positive patient‑reported outcomes. These secondary results are being further analyzed to determine their regulatory relevance and to guide future development decisions.
CEO Dr. Denise Scots‑Knight said, “In collaboration with our partner Ultragenyx, we have analysed a significant part of the data from the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta and continue to develop our understanding of the fracture data and the patient reported outcomes (PROs), especially in patients aged 2–18 years old. We believe that these data, which include pre‑specified sub‑groups and ad hoc analyses, may provide the basis for engagement with the regulatory agencies.” She added that the company will continue to assess the totality of the trial data to determine next steps, including potential interactions with regulators.
After the setrusumab trial results were released in January 2026, analysts lowered their price targets for Mereo, citing the failure to meet primary endpoints. The earnings report itself was in line with expectations, but the extended cash runway provides a cushion that may temper short‑term concerns and give the company time to evaluate the data and pursue regulatory engagement.
The company remains pre‑revenue, so its valuation is tied to the progress of its pipeline. The extended runway into mid‑2027 offers a tailwind that offsets the headwind of the setrusumab primary endpoint miss, while the company continues to monitor its other programs, such as alvelestat for alpha‑1 antitrypsin deficiency‑associated lung disease, and the out‑licensed vantictumab program. Investors will watch how the company translates the secondary endpoints into regulatory milestones and whether it can secure additional funding or partnerships to sustain its development trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.